Novonesis (novozymes)-ADRNVZMY
13F holders, Q3 2025 (September 30)9holders −2
1new positions
2sold out
$61.17avg. 13F price*
At the end of Q3 2025, 9 institutions reported holding Novonesis (novozymes)-ADR (NVZMY) in their 13F filings, down 2 from Q2 2025. 1 opened new positions and 2 sold out. The largest holders were Rhumbline Advisers ($625K), Sterling Capital Management LLC ($393K) and Boston Common Asset Management, LLC ($283K).
- Company
- Novonesis (novozymes)-ADR
- CUSIP
- 670108109
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $2K |
| Exits | 2 | $56K |
All 13F filers, Q2 2025 → Q3 2025: 1,811 shares bought and 1,223 shares sold, net +588 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Rhumbline Advisers | 0.00% | Reduce -2.6% | 10,232 | $625K |
| Sterling Capital Management LLC | 0.01% | Reduce -1.8% | 6,424 | $393K |
| Boston Common Asset Management, LLC | 0.01% | Add +51.1% | 4,625 | $283K |
| S&co Inc. | 0.02% | No change | 4,500 | $275K |
| GAMMA Investing LLC | 0.01% | Add +1.6% | 2,401 | $147K |
| PNC Financial Services Group, Inc. | 0.00% | Reduce -3.0% | 1,577 | $96K |
| Salomon & Ludwin, LLC | 0.00% | Add +3620.0% | 186 | $11K |
| Copeland Capital Management, LLC | 0.00% | No change | 49 | $3K |
| Ameriflex Group, Inc. | 0.00% | New | 28 | $2K |
"% of holder's portfolio" is NVZMY's weight in each manager's 13F, not the share of Novonesis (novozymes)-ADR the manager owns.